Inactivated tumor suppressor Rb by nitric oxide promotes mitosis in human breast cancer cells

Journal of Cellular Biochemistry

Volumn 92, Issue 1, 2004, Pages 1-5

  Radisavljevic, Ziv ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Breast cancer; Mitosis; Nitric oxide; p53; Rb; Signaling

Indexed keywords

NITRIC OXIDE; PROTEIN P53; RETINOBLASTOMA PROTEIN; TUMOR SUPPRESSOR PROTEIN; ARGININE; N(G) METHYLARGININE; SERINE;

ARTICLE; BREAST CANCER; CANCER CELL; CELL CYCLE G2 PHASE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; HUMAN; HUMAN CELL; MITOSIS; PHOSPHORYLATION; PRIORITY JOURNAL; BREAST TUMOR; CARCINOMA; FEMALE; METABOLISM; TUMOR CELL LINE;

ARGININE; BREAST NEOPLASMS; CARCINOMA; CELL LINE, TUMOR; FEMALE; HUMANS; MITOSIS; NITRIC OXIDE; OMEGA-N-METHYLARGININE; PHOSPHORYLATION; RETINOBLASTOMA PROTEIN; SERINE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 16544369424     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.20063     Document Type: Article

References (25)

1. Alarcon R, Koumenis C, Geyer RK, Maki CG, Giaccia AJ. 1999. Hypoxia induces p53 accumulation through MDM2 down-regulation and inhibition of E6-mediated degradation. Cancer Res 59:6046-6051.
2. Dumaz N, Meek DW. 1999. Serine15 phosphorylation stimulates p53 transactivation but does not directly influence interaction with HDM2. EMBO J 18:7002-7010.
3. Dyson N. 1998. The regulation of E2F by pRB-family proteins. Genes Dev 12:2245-2262.
4. Harris SR, Schoeffner DJ, Yoshiji H, Thorgeirsson UP. 2002. Tumor growth enhancing effects of vascular endothelial growth factor are associated with increased nitric oxide synthase activity and inhibition of apoptosis in human breast carcinoma xenografts. Cancer Lett 179:95-101.
5. Hatakeyama M, Weinberg RA. 1995. The role of RB in cell cycle control. Prog Cell Cycle Res 1:9-19.
6. Ji YS, Johnson BH, Webb MS, Thompson EB. 2002. Mutational analysis of DBD a unique antileukemic gene sequence. Neoplasia 4:417-423.
7. Kampa M, Hatzoglou A, Notas G, Niniraki M, Kouroumalis E, Castanas E. 2001. Opioids are non-competitive inhibitors of nitric oxide synthase in T47D human breast cancer cells. Cell Death Differ 8:943-952.
8. Kapoor M, Hamm R, Yan W, Taya Y, Lozano G. 2000. Cooperative phosphorylation at multiple sites is required to activate p53 in response to UV radiation. Oncogene 19:358-364.
9. Levine AJ. 1997. p53, the cellular gatekeeper for growth and division. Cell 88:323-331.
10. Loden M, Stighall M, Nielsen NH, Roos G, Emdin SO, Ostlund H, Landberg G. 2002. The cyclin D1 high and cyclin E high subgroups of breast cancer: separate pathways in tumorogenesis based on pattern of genetic aberrations and inactivation of the pRb node. Oncogene 21:4680-4690.
11. Hetzen E, Zhou J, Jelkmann W, Fandrey J, Brune B. 2003. Nitric oxide impairs normoxic degradation of HIF-1α by inhibition of prolyl hydroxylases. Mol Biol Cell 14:3470-3481.
12. Morgan DO. 1997. Cyclin-dependent kinases: engines, clocks, and microprocessors. Annu Rev Cell Dev Biol 13:261-291.
13. Mortensen K, Skouv J, Hougaard DM, Larsson LI. 1999. Endogenous endothelial cell nitric-oxide synthase modulates apoptosis in cultured breast cancer cells and is transcriptionally regulated by p53. J Biol Chem 274:37679-37684.
14. Nath N, Wang S, Betts V, Knudsen E, Chellappan S. 2003. Apoptotic and mitogenic stimuli inactivate Rb by differential utilization of p38 and cyclin-dependent kinases. Oncogene 22:5986-5994.
15. Oren M. 1999. Regulation of the p53 tumor suppressor protein. J Biol Chem 274:36031-36034.
16. Plachta N, Traister A, Weil M. 2003. Nitric oxide is involved in establishing the balance between cell cycle progression and cell death in the developing neural tube. Exp Cell Res 288:354-362.
17. Radisavljevic Z. 2003. Nitric oxide suppression triggers apoptosis through the FKHRL1 (FOXO3a)/ROCK kinase pathway in human breast carcinoma cells. Cancer 97:1358-1363.
18. Radisavljevic Z, Avraham H, Avraham S. 2000. Vascular endothelial growth factor up-regulates ICAM-1 expression via the phosphatidylinositol 3 OH-kinase/AKT/nitric oxide pathway and modulates migration of brain microvascular endothelial cells. J Biol Chem 275:20770-20774.
19. Reveneau S, Arnould L, Jolimoy G, Hilpert S, Lejeune P, Saint-Giorgio V, Belichard C, Jeannin JF. 1999. Nitric oxide synthase in human breast cancer is associated with tumor grade, proliferation rate, and expression of progesterone receptors. Lab Invest 79:1215-1225.
20. Scudiero DA, Shoemaker RH, Paull KD, Monks A, Tierney S, Nofziger TH, Currens MJ, Seniff D, Boyd MR. 1988. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res 48:4827-4833.
21. Senderowicz AM. 2000. Small molecule modulators of cyclin-dependent kinases for cancer therapy. Oncogene 19:6600-6606.
22. Sherr CJ. 1996. Cancer cell cycles. Science 274:1672-1677.
23. Thut CJ, Goodrich JA, Tjian R. 1997. Repression of p53-mediated transcription by MDM2: A dual mechanism. Genes Dev 11:1974-1986.
24. Vakkala M, Kahlos K, Lakari E, Paakko P, Kinnula V, Soini Y. 2000. Inducible nitric oxide synthase expression, apoptosis, and angiogenesis in in situ and invasive breast carcinomas. Clin Cancer Res 6:2408-2416.
25. Weinberg RA. 1995. The retinoblastoma protein and cell cycle control. Cell 81:323-330.